Posted on by admin

Liver Cancer Pipeline Outlook, FDA Approvals, Clinical Trials and Companies 2024 (Updated)

Liver Cancer Pipeline Outlook, FDA Approvals, Clinical Trials and Companies 2024 (Updated)

DelveInsight, “Liver Cancer Pipeline Insight 2024” report provides comprehensive insights about 70+ Liver Cancer companies and 75+ pipeline drugs in the Liver Cancer pipeline landscape. It covers the Liver Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Liver Cancer therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Key Takeaways from the Liver Cancer Pipeline Report

  • DelveInsight’s Liver Cancer Pipeline analysis depicts a robust space with 70+ active players working to develop 75+ pipeline treatment therapies.

  • The leading Liver Cancer Companies working in the market include Arcus Biosciences, Yiviva, Virogin Biotech, Tvardi Therapeutics, GlaxoSmithKline, TORL Biotherapeutics, AVEO Pharmaceuticals, Teclison, Epizyme, Sirnaomics, Coherus Biosciences, Sinocelltech Ltd., Qurient Co, Hoffmann-La Roche, Can-Fite BioPharma, Omega Therapeutics, Novita Pharmaceuticals, and Bristol-Myers Squibb, and others.

  • Promising Liver Cancer Therapies in the various stages of development include Atezolizumab, Bevacizumab, Tiragolumab, OH2 injection, MTL-CEBPA, Sorafenib 200mg, Lipiodol, Pemetrexed, Exatecan Mesylate, Brivanib, and others.

  • May 2024:- Target PharmaSolutions Inc.- A Longitudinal Observational Study of the Natural History and Management of Patients With Hepatocellular Carcinoma.  TARGET-HCC is a longitudinal, observational study of patients being managed for HCC in usual clinical practice. TARGET-HCC will create a research registry of participants with HCC within academic and community real-world practices in order to assess the safety and effectiveness of the entire spectrum of current and future therapies across diverse populations.

  • May 2024:- Eureka Therapeutics Inc.– An Open-Label, Dose Escalation, Multi-Center Phase I/II Clinical Trial of ECT204 T-Cell Therapy in Adults With Advanced Hepatocellular Carcinoma (HCC) (ARYA-3). This is an open-label, dose escalation, multi-center, Phase I/II clinical trial. The purpose of this study is to evaluate an investigational ARTEMIS® ECT204 T-cell therapy in adult patients with GPC3-positive advanced hepatocellular carcinoma (HCC). In this study, a patient’s T cells are collected and genetically modified to express Eureka’s proprietary anti-GPC3 ARTEMIS T cell receptors (AbTCR). These modified T cells are then reintroduced into the patient to specifically seek out and destroy GPC3-expressing cancer cells.

 

Request a sample and discover the recent advances in Liver Cancer Treatment Drugs @ Liver Cancer Pipeline Outlook Report

 

In the Liver Cancer pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Liver Cancer collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

 

Liver Cancer Overview

Liver cancer is a cancer that originates in the liver, and is an aggressive tumor that frequently occurs in the setting of chronic liver disease and cirrhosis. Primary liver cancer, or hepatocellular carcinoma (HCC), is the fifth most common cancer in males and the seventh most common cancer in females, and is the third leading cause of cancer-related death worldwide. Hepatocellular carcinoma (HCC), the primary cancer of the liver, is derived from hepatocytes and occurs in more than approximately 80% of cases of liver cancer. The HCC carcinogenesis is often associated with liver cirrhosis resulting from chronic liver diseases such as chronic hepatitis, HBV or HCV infection, and autoimmune hepatitis. .

 

 

Liver Cancer Emerging Drugs Profile

 

  • Namodenoson: Can-Fite BioPharma

Namodenoson is an oral small molecule drug generically known as Cl-IB-MECA (2-chloro-N6-(3-iodobenzyl)-adenosine-5′- N-methyl-uronamide), a highly specific and selective agonist at the A3 adenosine receptor (A3AR). Namodenoson’s mechanism of action is mediated via deregulation of the NF-κB and Wnt signal transduction pathways, resulting in the apoptosis of tumor cells. The protective effect of Namodenoson is mediated via down-regulation of the NF-kB signal transduction pathway and preventing apoptosis. Namodenoson has a potent anti-cancer effect, particularly against hepatocellular carcinoma, and anti-inflammatory activity demonstrated in pre-clinical animal models of liver inflammation.

 

  • YIV-906: Yiviva

YIV-906 (also PHY906 or KD018) is a therapeutic candidate comprised of a proprietary cGMP botanical extract of four herbs inspired by a traditional Chinese medicine formulation used for over a millennium. YIV-906 has the potential to be developed as a platform oncology therapeutic when administered in combination with chemotherapy, immunotherapy and radiation therapies, in multiple cancer indications. YIV-906 has been shown to enhance immune function in the tumor microenvironment (by polarizing M1 macrophages and activating T cells), protect the gastrointestinal tract (by inhibiting inflammation via IL-6, NF-kappa-B, COX2, and iNOS pathways) and promote intestinal tissue repair (by increasing activity and expression of components of the Wnt signaling pathway). YIV-906 has been observed to enhance the anti-tumor activity of sorafenib in preclinical models of hepatocellular carcinoma and has shown promise in preliminary clinical studies in liver, pancreatic, colorectal and rectal cancers. Currently, the drug is in Phase II stage of its clincal trial for the treatment of liver cancer.

 

  • TTI-101: Tvardi Therapeutics

TTI-101 is an orally bioavailable, small-molecule inhibitor of signal transducer and activator of transcription 3 (STAT3), a transcription factor whose upregulation and activation governs many hallmarks of cancer, inflammation, and fibrosis. Preclinically, TTI-101 has demonstrated an excellent pharmacokinetic profile, potency in attenuating pY705-STAT3 phosphorylation, and efficacy in inhibiting tumor growth in xenograft and syngeneic tumor models. Currently, the drug is in the Phase II stage of clinical trial.

 

  • STP707: Sirnaomics

STP707, our second key product, is in early-stage development for the treatment of solid tumors, liver cancer. STP707 is an intravenously administered TGF-ß1 and COX-2 inhibitor that leverages an RNAi-based response using the company’s proprietary PNP delivery platform. Currently, the drug is in Phase I stage of its clinical trial for the treatment of liver cancer.

 

Learn more about Liver Cancer in Clinical Trials @ Liver Cancer Drugs

 

Liver Cancer Therapeutics Assessment

There are approx. 70+ key Liver Cancer companies which are developing the therapies Liver Cancer. The Liver Cancer companies which have their Liver Cancer drug candidates in the most advanced stage, i.e. phase III include, Can-Fite BioPharma.

 

DelveInsight’s Liver Cancer pipeline report covers around 75+ products under different phases of clinical development like

  • Late stage products (Phase III)

  • Mid-stage products (Phase II)

  • Early-stage product (Phase I) along with the details of

  • Pre-clinical and Discovery stage candidates

  • Discontinued & Inactive candidates

 

Discover more about Liver Cancer in development @ Liver Cancer Clinical Trials

 

Liver Cancer Companies

Arcus Biosciences, Yiviva, Virogin Biotech, Tvardi Therapeutics, GlaxoSmithKline, TORL Biotherapeutics, AVEO Pharmaceuticals, Teclison, Epizyme, Sirnaomics, Coherus Biosciences, Sinocelltech Ltd., Qurient Co, Hoffmann-La Roche, Can-Fite BioPharma, Omega Therapeutics, Novita Pharmaceuticals, and Bristol-Myers Squibb, and others.

 

Liver Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Intra-articular

  • Intraocular

  • Intrathecal

  • Intravenous

  • Oral

  • Parenteral

  • Subcutaneous

  • Topical

  • Transdermal

 

Liver Cancer Products have been categorized under various Molecule types such as

  • Oligonucleotide

  • Peptide

  • Small molecule

 

To know more about Liver Cancer, visit @ Liver Cancer Segmentation

 

Scope of the Liver Cancer Pipeline Report

  • Coverage- Global

  • Liver Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination

  • Liver Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

  • Liver Cancer Companies- Arcus Biosciences, Yiviva, Virogin Biotech, Tvardi Therapeutics, GlaxoSmithKline, TORL Biotherapeutics, AVEO Pharmaceuticals, Teclison, Epizyme, Sirnaomics, Coherus Biosciences, Sinocelltech Ltd., Qurient Co, Hoffmann-La Roche, Can-Fite BioPharma, Omega Therapeutics, Novita Pharmaceuticals, and Bristol-Myers Squibb, and others.

  • Liver Cancer Therapies- Atezolizumab, Bevacizumab, Tiragolumab, OH2 injection, MTL-CEBPA, Sorafenib 200mg, Lipiodol, Pemetrexed, Exatecan Mesylate, Brivanib, and others.

 

For further information on the Liver Cancer Pipeline Therapeutics, reach out @ Liver Cancer Products Development

 

Table of Content

  1. Introduction

  2. Executive Summary

  3. Liver Cancer: Overview

  4. Pipeline Therapeutics

  5. Therapeutic Assessment

  6. Liver Cancer – DelveInsight’s Analytical Perspective

  7. Late Stage Products (Phase III)

  8. Namodenoson: Can-Fite BioPharma

  9. Drug profiles in the detailed report…..

  10. Mid Stage Products (Phase II)

  11. YIV-906: Yiviva

  12. Drug profiles in the detailed report…..

  13. Early Stage Products (Phase I)

  14. STP707: Sirnaomics

  15. Mid Stage Products (Phase II)

  16. Preclinical Stage Products

  17. Drug Name: Company Name

  18. Drug profiles in the detailed report…..

  19. Inactive Products

  20. Liver Cancer – Collaborations Assessment- Licensing / Partnering / Funding

  21. Liver Cancer – Unmet Needs

  22. Liver Cancer – Market Drivers and Barriers

  23. Appendix

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/